Labour induction with an intermediate-dose oxytocin regimen has advantages over a high-dose regimen

被引:6
|
作者
Manjula, B. G. [1 ]
Bagga, R. [1 ]
Kalra, J. [1 ]
Dutta, S. [2 ]
机构
[1] Post Grad Inst Med Educ & Res, Dept Obstet & Gynaecol, Chandigarh 160012, India
[2] Post Grad Inst Med Educ & Res, Dept Neonatol, Chandigarh 160012, India
关键词
Induction; intermediate-dose; labour; oxytocin; NEONATAL HYPERBILIRUBINEMIA; MISOPROSTOL; RECEPTOR; WOMEN;
D O I
10.3109/01443615.2014.968103
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
A total of 200 women planned for labour induction were randomised to receive high-dose oxytocin (6 mU/min with similar increments every 45 min) or intermediate-dose oxytocin (3 mU/min with similar increments every 45 min). Oxytocin solution was prepared with 30 units in 500 ml saline with which the infusion rate in ml/h is numerically equal to oxytocin in mU/min. We observed that the caesarean rate (18% vs 6%, p = 0.009), contraction abnormalities (35% vs 14%, p = 0.0005) and neonatal bilirubin levels (7.99 +/- 2.70 vs 6.80 +/- 2.65, p = 0.002) were higher with high-dose than with intermediate-dose. The induction-delivery interval (IDI) was similar (10 h 13 min with high-dose and 11 h 5 min with intermediatedose; p = 0.237, NS). Nulliparous women benefited more with intermediate-dose as the caesarean rate was higher with high-dose (24.6% vs 7.9%, p = 0.011). Although the caesarean rate was higher in multiparous women with high-dose oxytocin, it was statistically not significant (5.7% vs 2.7%; p = 0.609). Oxytocin regimens for labour induction are usually high-dose (4-6 mU/min) or low-dose (1-1.5 mU/min). The former is associated with more contraction abnormalities and the latter with prolonged IDI; both result in an increased caesarean rate. In order to off set these disadvantages, an intermediate-dose regimen was selected. The increment interval of 45 min was selected in accordance with the pharmacokinetics of oxytocin. We observed a lower caesarean rate when compared with the high-dose regimen, without any increase in the IDI. Hence, we propose that the intermediate-dose oxytocin regimen should be preferred to the high-dose regimen for labour induction.
引用
收藏
页码:362 / 367
页数:6
相关论文
共 50 条
  • [1] Induction of labour with oxytocin: is an intermediate-dose regimen better?
    Manjula, B. G.
    Kalra, J.
    Dutta, S.
    BJOG-AN INTERNATIONAL JOURNAL OF OBSTETRICS AND GYNAECOLOGY, 2014, 121 : 108 - 108
  • [2] Prophylactic treatment for severe haemophilia: comparison of an intermediate-dose to a high-dose regimen
    Fischer, K
    Astermark, J
    Van der Bom, JG
    Ljung, R
    Berntorp, E
    Grobbee, DE
    Van den Berg, HM
    HAEMOPHILIA, 2002, 8 (06) : 753 - 760
  • [3] A HIGH-DOSE TAMOXIFEN REGIMEN
    SHAIKH, NA
    GHILCHIK, MW
    BRITISH JOURNAL OF CANCER, 1987, 56 (06) : 870 - 870
  • [4] Efficacy of high-dose cytarabine and aclarubicin in combination with G-CSF regimen compared to intermediate/high-dose cytarabine and standard-dose cytarabine induction regimen for non-remission acute myeloid leukemia
    Lei, Meiqing
    Liu, Limin
    Wang, Zhiming
    Wu, Depei
    INDIAN JOURNAL OF CANCER, 2019, 56 (02) : 167 - 172
  • [5] High-dose versus low-dose oxytocin infusion for induction of labour: a systematic review
    Budden, A.
    Chen, L.
    Henry, A.
    BJOG-AN INTERNATIONAL JOURNAL OF OBSTETRICS AND GYNAECOLOGY, 2015, 122 : 163 - 163
  • [6] High-dose versus low-dose oxytocin infusion regimens for induction of labour at term
    Budden, Aaron
    Chen, Lily J. Y.
    Henry, Amanda
    COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2014, (10):
  • [7] High-dose compared with low-dose oxytocin for induction of labour of nulliparous women at term
    Prichard, Natasha
    Lindquist, Anthea
    Hiscock, Richard
    Ruff, Sophie
    Tong, Stephen
    Brownfoot, Fiona C.
    JOURNAL OF MATERNAL-FETAL & NEONATAL MEDICINE, 2019, 32 (03): : 362 - 368
  • [8] MEC (MITOXANTRONE, ETOPOSIDE AND INTERMEDIATE-DOSE CYTARABINE) - AN EFFECTIVE INDUCTION REGIMEN FOR PREVIOUSLY UNTREATED ACUTE NONLYMPHOCYTIC LEUKEMIA
    VISANI, G
    PETTI, MC
    CENACCHI, A
    MANFROI, S
    TOSI, P
    SPADEA, A
    LATAGLIATA, R
    AMADORI, S
    MANDELLI, F
    TURA, S
    LEUKEMIA & LYMPHOMA, 1995, 19 (5-6) : 447 - 451
  • [9] MITOMYCIN-C ADMINISTERED BY A HIGH-DOSE INDUCTION REGIMEN IN THE TREATMENT OF CANCER
    PATTON, AJ
    KNIGHT, EW
    TENNANT, JD
    PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, 1979, 20 (MAR): : 387 - 387
  • [10] HIGH-DOSE AND INTERMEDIATE-DOSE CYTOSINE-ARABINOSIDE IN THE TREATMENT OF SECONDARY LEUKEMIAS
    LEITHA, T
    JAGER, U
    SCHWARZINGER, I
    BETTELHEIM, P
    HINTERBERGER, W
    NEUMANN, E
    KORNINGER, C
    KYRLE, PA
    HAAS, O
    SCHLAPPACK, O
    LECHNER, K
    WIENER KLINISCHE WOCHENSCHRIFT, 1988, 100 (15) : 509 - 514